Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Onalespib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 15 Jan 2019 Planned primary completion date changed from 30 Jun 2018 to 31 Mar 2019.
- 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated